While first-line EGFR inhibitors have revolutionized the treatment of mutant lung cancer, the inevitable development of therapeutic resistance remains a primary clinical hurdle. In this interview with Helena Yu, MD, thoracic medical oncologist at Memorial Sloan Kettering Cancer Center, we explore the evolving landscape of "what comes next" when standard targeted therapies fail. The transition begins with a critical re-biopsy to determine the mechanism of progression. In approximately 25% of cases, a new targetable mutation—such as MET amplification or a secondary EGFR mutation—is identified, allowing for a continuation of targeted approaches.
Key Takeaways:
1. The "75% Gap": Resistance is Often Targetless
While re-biopsies are critical to look for "targetable" resistance (like MET amplification or secondary EGFR mutations), they only yield actionable results for about 25% of patients.
2. ADCs are the New Standard for Post-TKI Care
Antibody-drug conjugates (ADCs) have emerged as the primary solution for patients who have progressed on EGFR inhibitors and chemotherapy.
3. Strategic Focus on "Hard-to-Treat" Phenotypes
Managing EGFR-mutant cancer in 2026 requires specialized strategies for high-risk scenarios.
However, for the remaining 75% of patients, no clear genomic target is found. This "biomarker agnostic" group requires a shift in strategy. A significant breakthrough discussed is the recent approval of datopotamab deruxtecan (Dato-DXd; Datroway). As a TROP2-directed antibody-drug conjugate (ADC), it offers a much-needed second-line option for patients who have already progressed through both EGFR-targeted inhibitors and standard chemotherapy.
Beyond genomic resistance, the discussion highlights two particularly difficult clinical scenarios:
- Histologic Transformation: In about 15% of patients, the cancer physically morphs from adenocarcinoma into squamous or small-cell lung cancer. This shift renders existing EGFR treatments ineffective and requires an entirely different chemotherapy paradigm. Current research is heavily focused on preventing this transformation before it occurs.
- CNS Disease: With nearly two-thirds of EGFR-mutant patients developing brain metastases or leptomeningeal disease, the need for therapies with high central nervous system (CNS) penetration is urgent.
Ultimately, the interview underscores that while the "easy" targets have been addressed, the next frontier of lung cancer care lies in managing complex resistance patterns and ensuring that patients with advanced CNS involvement have access to the latest clinical trials.
